Expression of GOLPH2 is associated with the progression of and poor prognosis in gastric cancer

Abstract

Golgi phosphoprotein 2 (GOLPH2) has been associated with the development and progression of various human cancers. The aims of this study were to investigate the relationship between GOLPH2 and gastric cancer (GC) progression and explore the clinical significance of GOLPH2 in GC. GOLPH2 expression was examined in four pairs of primary GC tissues and the adjacent non-cancerous tissues from the same patients, using immunohistochemistry (IHC), quantitative PCR and western blotting. Furthermore, GOLPH2 protein expression was analyzed in 10 normal gastric tissues and 385 clinicopathologically characterized cases of GC by IHC. Statistical analyses were performed to determine the prognostic and diagnostic associations. GOLPH2 mRNA and protein expression were both markedly upregulated in GC tissues, compared with the paired adjacent non-cancerous tissues. The Chi-square test and Spearman analysis revealed a significant correlation between GOLPH2 expression and clinical stage, T classification, lymph node metastasis, metastasis and venous invasion. Patients with a higher GOLPH2 expression had a shorter overall survival (OS), compared to patients with lower GOLPH2 expression. Notably, our results suggested that GOLPH2 is associated with the development and progression of GC. Therefore, additional studies focusing on the potential of GOLPH2 as a novel therapeutic target in GC are required.

High GP73 expression correlates with poor response to neoadjuvant chemotherapy and survival in gastric cancer

“…In the present study, we observed that patients with higher GP73 expression have a signi cantly lower overall survival rate than those with low or none GP73 expression, and multivariate analysis revealed GP73 expression was an independent predictor for survival. These results were in accordance with a study of Liu et al, who analyzed the GP73 expression by IHC in 385 gastric cancer patients, and found that GP73 is a useful prognostic variable of overall survival in gastric cancer patients [10]. Our results, with previous reports, may indicate that GP73 may have the potential to be a new target in the treatment of gastric cancer.…”

“…A study from Chen et al assessed GP73 protein expression by immunohistochemistry in both tumor and nontumorous gastric mucosal tissue, they found GP73 was down-regulated in gastric cancer, and its expression in gastric cancer was associated with tumor differentiation [9]. Liu et al's study revealed a signi cant correlation between GP73 expression and clinical stage, lymph node metastasis and venous invasion, thus the study made a conclusion that GP73 expression may be associated with tumor progression [10], However, in the present study, no signi cant correlation was found between GP73 expression and clinical variables including age, differentiation and TNM stage, this discrepancy may be explained as the following: rstly, a comparatively more gastric cancer samples was enrolled in the present study, the difference of patient clinical characteristics as a selection bias may in uence the analysis. Secondly, we assessed GP73 expression by IHC on TMA, and it may, to some extent, reduce the experimental bias as compared to IHC on a separate para n tissue.…”

“…Most studies showed that GP73 was over-expressed and was correlated with tumor progression and poor survival in patients with several types of cancer including hepatocellular carcinoma, colon cancer [7,8]. The association between GP73 and gastric cancer remains controversial, GP73 was reported to be correlated with tumor differentiation in gastric cancer [9], however, other study found the correlation between GP73 and patient survival [10].…”

High GP73 Expression Correlates With Poor Response to Neoadjuvant Chemotherapy and Survival in Gastric Cancer: A Tissue Microarray Study

“…The role of GP73 in gastric cancer remains unclear, GP73 was reported to be correlated with tumor differentiation in gastric cancer [9]. Others found the correlation between GP73 and patient survival [10].…”

Golgi-Related Proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in Cutaneous Melanoma: Patterns of Expression and Prognostic Significance

“…Initially, GOLPH2 upregulation was reported in neoplastic and non-neoplastic liver pathologies, and a number of studies postulated its serum level as a novel marker of hepatocellular carcinoma [2,3,4,5,6,7,8]. Subsequently, enhanced GOLPH2 expression was reported in other cancer settings [9,10,11,12,13,14,15]. To the best of our knowledge, GOLPH2 expression in melanoma patients has not been previously analyzed.…”